Prism Medico and Pharmacy's latest annual report highlights a significant strategic shift.

The company recorded a profit of Rs. 0.32 Cr for the financial year, a turnaround from a loss in the previous year, with revenue from operations growing to Rs. 2.44 Cr.

The Board has proposed a major change in the use of preferential issue funds, reallocating Rs. 23 Cr originally for internal manufacturing setup towards a strategic investment in Infuze Well Private Limited (IWPL). This move aims to acquire a controlling 71.32% stake in IWPL, making it a subsidiary and accelerating manufacturing capabilities with lower risk.

The company also sought approval for general related party transactions up to Rs. 70 Cr for the upcoming year.